Who can prepare DSCSA documentation for your pharmacy: the six options in 2026

There is no such thing as a certified DSCSA preparer. The FDA does not license one, does not maintain a list of them, and, for a small business dispenser relying on the exemption, does not want anything filed at all. So the question is not who is allowed to prepare your documentation. It is who is actually willing to sit down and write it, and which of them is the right fit for the gap you have.

Six kinds of organisation do this work for independent pharmacies. This page names them, quotes each one from its own website with the date that quote was retrieved, and says plainly where each stops, including where DoseTrace stops.

The six options, side by side

Can a pharmacy write its own DSCSA documentation?

Yes, and a pharmacy that does owes nobody anything. The starting point is DispenserEDU, which describes itself as “A resource page developed collaboratively among supply chain trading partners to house educational information dispensers may find useful to assist in implementation of the DSCSA,” and identifies those partners by carrying their logos: APhA, ASHP, HDA, NABP, NCPA, PDG and PDSA. Those are the pharmacy profession’s own associations together with the distributor and standards bodies, not a company with something to sell. It publishes no price because it charges nothing.

The limit is structural rather than a matter of quality. Educational material explains what section 582 of the FD&C Act asks for. It cannot contain a particular pharmacy’s exemption determination, its dated standard operating procedures, its named authorized trading partners or its staff’s training attestations, because none of those facts are known to it. Every pharmacy should read DispenserEDU first. What is being bought from anyone further down this page is the writing time, not the knowledge.

Can a DSCSA software vendor prepare my documentation?

No, and this is the most common and most expensive misunderstanding in this market. Track-and-trace platforms sell data infrastructure, and they say so. InfiniTrak describes itself as “an all-in-one compliance solution designed specifically for dispensers” and as “the only DSCSA software integrated with BestRx, PrimeRx, PioneerRx, Liberty Software and 30 more leading pharmacy management systems.” LSPedia sells “DSCSA Compliance Software and EPCIS Solutions”, the OneScan suite, with modules for authorized trading partners, suspect order monitoring and returns.

Both do a real job well. Neither writes a policy document, and neither claims to. The tell is in the FDA’s own language: the exemption letter that governs small business dispensers uses the words “software” and “vendor” zero times each. What it asks for, obligation by obligation, is “systems and processes.” A platform is the system. The processes have to be written down by someone. The full comparison of software against a written record takes that apart in detail. Neither vendor publishes a price: as of 7 August 2026, infinitrak.us/pricing returns a 404 and lspedia.com/pricing returns a 404, and both sites route to a sales conversation.

Can a pharmacy compliance consultant do it?

Yes, and this is the closest thing to a direct competitor for the written half of the work. PRS Pharmacy Services sells DSCSA360, “PRS and Advasur have partnered to provide DSCSA 360™”, which bundles an “Easy to follow Compliance Guide,” “Required Policies and Procedures/SOPs,” “Required forms,” employee training, and an EPCIS data feed from authorized trading partners into one subscription. That is a broader offering than ours and it would be dishonest to present it otherwise: it covers the written record and the ongoing data feed, where DoseTrace covers only the first.

It is also the only company in this market with a published fee table, though it is not on the product page: the fees sit in Attachment B of the service agreement on the sign-up portal, at $115/month per location for a community pharmacy and $83/month discounted, rising to $350 and $293 for long-term care or specialty. What DSCSA compliance actually costs an independent pharmacy quotes those fees with the date they were retrieved and shows the arithmetic against a one-time fee. The decision between a subscription and a one-time preparation is not about which is cheaper, it is about whether your gap is a continuing one or a finished one.

Can a pharmacy-only DSCSA platform prepare the documentation?

Partly, and this category is worth separating from general track-and-trace software because it is aimed at nobody else. Advasur sells Advasur 360 to pharmacies only, “Built by pharmacists, for pharmacists”, and its published checklist covers supplier setup, Authorized Trading Partner status, receipt of transaction information and transaction statements, a missing-data workflow, suspect product, staff training, six-year retention and record retrieval. That is wider than a data pipe and wider than a document set.

It is also the one company in this market that states our own argument out loud. Jim Shaver, Managing Director of Advasur 360, is quoted on that page: “A good DSCSA checklist should not just help a pharmacy say the work was done. It should help the pharmacy show the work was done.” We agree with that sentence completely, and a pharmacy persuaded by it should read their material.

The difference is shape rather than quality. Advasur 360 is an ongoing process a pharmacy runs, it turns a checklist into a workflow and keeps it running, entered through a 30-minute readiness review, with no price published anywhere on the site (advasur.com/pricing returned 404 when probed on 7 August 2026, and no dollar figure appears anywhere on advasur.com, the fee table above is published by PRS, its partner on DSCSA360, not by Advasur). DoseTrace is a finished artefact: nine dated documents, delivered once, for $99. If your pharmacy needs the receiving process itself fixed and kept fixed, that is a platform purchase. If the process is already working and only the written record is missing, buying a subscription to obtain it is the expensive route.

Can a healthcare attorney prepare DSCSA documentation?

Yes, and law firms with pharmacy regulatory practices actively market this. Oberheiden P.C. runs a DSCSA compliance practice led by attorney Lynette Byrd, a former DOJ attorney, and frames the work as helping pharmacies implement “policies, procedures, and protocols designed to ensure strict DSCSA compliance,” noting that gaps “can lead to significant consequences in DEA audits and investigations.” No fee is published; a firm like this quotes an engagement.

When a lawyer is the right answer and a documentation service is not

There are three situations where a pharmacy should call a healthcare regulatory attorney and should not start with a documentation service, including this one.

• An inspection, audit or investigation is already open. Once a DEA or FDA inquiry exists, the documents a pharmacy produces are evidence, and what gets written down and how it is characterised is a legal judgement. A binder prepared without counsel at that point can make matters worse.
• You need the analysis protected. A frank internal assessment of where a pharmacy has fallen short is a different thing when it is covered by attorney-client privilege than when it sits in a vendor’s file. If the honest answer to “have we been compliant since 2023?” is uncomfortable, ask a lawyer before you ask anyone else.
• The question is genuinely legal rather than documentary. Whether a multi-entity ownership structure counts as one corporate entity for the 25-employee threshold, or how DSCSA duties interact with a state board’s own rules, is legal advice. DoseTrace is not a law firm and does not give it.

Outside those three, a law firm is an expensive way to obtain a set of documents whose content is not actually in dispute. Most independent pharmacies approaching the November 2026 date are in the ordinary case: nothing has gone wrong, nobody is asking questions yet, and the gap is simply that the record was never written down.

What DoseTrace does, and where it stops

DoseTrace prepares the documentation and nothing else: a nine-document DSCSA readiness binder built from a 15-minute intake, every document dated, for $99 flat, one time. No subscription, no per-store multiplier, no integration and no data feed. If the transaction data itself is the problem, a platform or a consultant is the right purchase and this is not. If the problem is that an inspector asking today for a dated exemption determination, a written SOP and a training attestation would be handed nothing, that is what the binder is.

The question that decides this before you pick anyone

Confirm which exemption track your pharmacy is on first, because it changes both the deadline and the urgency. The FDA’s exemptions for small business dispensers now run “until November 27, 2027” under a letter issued 6 August 2026, and reach a pharmacy only if the corporate entity that owns it has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians, counted across the whole company rather than per store, and counted on one fixed day: 27 November 2024 for the window running now, 27 November 2026 for the extra year.

This is also the first practical test of anyone you are about to pay. When we retrieved InfiniTrak’s home page on 7 August 2026, the day after FDA published the extension, and the last date we checked it, it still headlined “Small Pharmacy DSCSA Deadline: November 27, 2026.” That is not a criticism of a company with no relationship to DoseTrace; a day is nothing. But before you engage any of the six kinds of supplier below, ask which letter they are working from and what date it carries. A provider still selling against the superseded date in a month’s time is telling you something about how it tracks the rule it is charging you to follow.

If the company was over that line, the relief you may believe runs to November 2026 ran only to November 2025 and has already lapsed. That single misreading is the difference between a planned purchase and an urgent one. What the exemption never covered walks through the scope, and what actually changes on 27 November 2026 takes the six lettered obligations one at a time.

Check which track you are on, free, about a minute, and it stores nothing. Contact reaches a person.

The 27 November 2027 expiry, the 25-employee threshold and its as-of dates are quoted from the FDA document DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers Until November 27, 2027, issued 6 August 2026, retrieved and re-verified 11 August 2026; it supersedes the 12 July 2024 letter previously cited here, at the same address. InfiniTrak, LSPedia, DispenserEDU, Advasur and Oberheiden P.C. are quoted from their own sites as retrieved on 7 August 2026, and their 404 pricing routes were probed on the same date. DispenserEDU carries the seven associations as logos rather than as text. The DSCSA360 program contents are quoted from prsrx.com/compliance/dscsa360 and the fee table from Attachment B of the service agreement at dscsa.prsrxnetwork.com, both as retrieved on 7 August 2026; PRS removed the previously quoted “as low as $66/month” from its product page between 5 and 7 August 2026, and the cost guide carries the full correction. Every company named here is independent, with no relationship to DoseTrace, and DoseTrace is not affiliated with DispenserEDU or any of the associations behind it. Their own sites are the authority on their own products and prices, if something here disagrees with theirs, theirs is correct and we want to know. DoseTrace is not a law firm and nothing on this page is legal advice.